ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
DSM's venture capital arm has invested $2 million in Sol-Gel Technologies. The Israeli company's sol-gel technology enables room-temperature entrapment of organic and bioactive molecules in silica glass beads. According to DSM, delivery of the trapped ingredients can be controlled, a potentially valuable innovation for the pharmaceutical and cosmetic markets.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X